Ban electronic cigarettes until safety concerns are addressed, say researchers

Dec 07, 2010

Regulatory authorities should consider banning electronic cigarettes until safety concerns have been addressed, concludes research published online in Tobacco Control.

The researchers base their conclusions on an evaluation of six different brands of electronic delivery systems or ENDS. These are not , but are designed to look and feel like regular .

They are aimed at for use in places where cigarette smoking is not permitted as they don't produce smoke. They usually consist of a battery, an atomiser, and a replaceable cartridge containing nicotine suspended in propylene glycol and water.

The e-cigarettes analysed in the study were bought from online vendors and assessed on design features; the accuracy and clarity of labelling; and the quality of instruction leaflets and associated printed material either supplied with the product or available on the manufacturer's website.

The basic design of all the products was similar, but the design features varied considerably, the evaluation showed.

Fluid containing nicotine readily leaked out of most cartridges, and it was difficult to put together or take apart the devices without getting nicotine over the user's hands.

Cartridge labelling was very poor, with most replacement packs lacking any indication of cartridge content, expiry date, or health warnings.

Cartridges claiming to have no nicotine content looked identical to those claiming to have high nicotine content and they were indistinguishable once removed from their packs and wrappers.

All brands were sold with "ambiguous amounts of nicotine," with levels varying from 6 mg to 24 mg, and it was not clear if this referred to the cartridge itself or the fluid suspension.

Internet orders were often filled incorrectly, with the wrong strength of nicotine or kits or cartridges supplied.

Disposal of used cartridges containing nicotine was not adequately covered in any of the websites or accompanying instruction leaflets.

Safety features did not always work correctly and print and internet material often contained information or made claims for which there is currently no scientific evidence, say the authors.

Examples of this included: "Be careful to avoid inhaling any significant quantity of fluid. Although it gives you a slight tingling sensation, it is not harmful." And: "Within two weeks your lung capacity will increase by 30%...Wrinkles in your skin will become less noticeable."

Their findings prompt the authors to conclude: "Our observations provide evidence that regulators should consider removing ENDS from the market until design features, quality control, labelling, disposal and safety issues have been adequately addressed."

Explore further: Life expectancy gap widens between those with mental illness and general population

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Americans still making unhealthy choices, CDC reports

4 hours ago

(HealthDay)—The overall health of Americans isn't improving much, with about six in 10 people either overweight or obese and large numbers engaging in unhealthy behaviors like smoking, heavy drinking or ...

User comments : 0

More news stories

If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...